Clinical Trial Update: A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC) [Phase 2]

View source ↗

Summary

A Phase 2, double-blind, multiple-dose escalation study evaluated NKTR-118 (oral PEG-naloxol) for opioid-induced constipation, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid-induced Constipation

Drugs mentioned

• NKTR-118

Snippet

Sponsor: AstraZeneca | Conditions: Opioid Induced Constipation (OIC) | Phase 2 | Status: COMPLETED | Results posted: 2015-06-12